Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt recurrence. Here, we demonstrate the use of personalized circulating tumor DNA (ctDNA) profiling for detection of recurrence in breast cancer.
Introduction
Breast cancer is one of the most commonly diagnosed cancers worldwide and the second leading cause of cancer-related deaths in women (1). The current standard of care for women with primary (nonmetastatic) breast cancer is surgery, often followed with adjuvant therapy to eliminate microscopic minimal residual disease (2, 3) . Unfortunately, up to 30% of women who present with no evidence of disease following treatment with curative intent eventually relapse and die of metastatic breast cancer (4) . Current guidelines for disease surveillance recommend regular imaging and physical examinations, and additional testing upon presentation of symptoms (5) (6) (7) . However, imaging tests such as mammography, MRI, and PET/CT often suffer from significant false-negative and false-positive results (8) (9) (10) . Biochemical methodologies such as serum levels of cancer antigen 15-3 (CA 15-3) have limited sensitivity and accuracy in detecting micrometastases (11) (12) (13) and have not been widely incorporated into clinical guidelines (14) . Therefore, there is a compelling need to develop more sensitive technologies capable of detecting preclinical metastases and identifying patients with disease recurrence earlier.
Circulating tumor DNA (ctDNA) detectable in blood plasma has been shown to reflect the mutational signatures of the primary tumor and is emerging as a potential noninvasive biomarker for monitoring tumor progression across different cancer types. In breast cancer, previous studies have shown the potential utility of ctDNA to detect preclinical metastases and predict relapse following surgery and/or adjuvant therapy in patients with specific hotspot mutations (15, 16) , chromosomal rearrangement breakpoint junctions (17) , and amplifications (18) . However, up to 43% of patients with breast cancer do not have hotspot mutations and thus cannot be monitored using a driver gene approach. Therefore, a more comprehensive solution is needed for the surveillance of patients with breast cancer after primary treatment (16, 19, 20) .
We previously reported a personalized ctDNA profiling approach for early detection of lung cancer recurrence (21, 22) . In this study, we applied an improved version of the assay for tracking breast cancer recurrence following surgery and adjuvant therapy. The primary objective was to determine the "lead interval" between detection of ctDNA in plasma and clinical detection of overt metastatic disease. A secondary objective was to determine whether ctDNA in plasma can detect recurrent disease earlier than current clinical methods, such as imaging or biochemical markers.
Materials and Methods

Patients and samples
EBLIS is a multicenter, prospective cohort study, funded by Cancer Research UK and the National Institute for Health Research. Blood sample collection was conducted in accordance with the Declaration of Helsinki. All the patients provided written-informed consent prior to entry into the trial. The trial protocol was approved by the Riverside Research Ethics Committee REC:13/LO/115; IRAS:126462. All research staff were blinded as to patient outcomes.
After removing nine patients who did not fulfill the trial entry criteria, a cohort of 188 patients was followed up with semiannual blood sampling for cfDNA analysis, along with concomitant clinical examination, and biochemical measurements, including CA 15-3 ( Fig. 1 ). Eligible patients were 18 years or older, displayed no clinical evidence of metastatic disease, and were therefore considered free of disease after surgery and adjuvant chemotherapy. All patients had completed adjuvant chemotherapy within 3 years of entering the study and were considered high risk for breast cancer relapse (risk of mortality greater than 50% at 10 years without therapy, corresponding to a relapse rate of 65% at 10 years without treatment).
At the midpoint of the study (2 years), 50% of the predicted events (18 relapses, comprising one local recurrence and 17 patients with distant relapse) were observed. Following an interim analysis, the EBLIS Trial Management group recommended an interim laboratory assessment of serial plasma in the first 49 patients. The 49 patients included all 18 relapses and comprised an approximately 1:2 ratio of relapsed to nonrelapsed patients. Relapsed and nonrelapsed patients were sequential patients recruited over the same time frame. We performed whole-exome analysis of the archived primary tumor for each patient for custom assay design. Serial plasma samples were analyzed in a blinded manner. Detailed description of blood sample collection, plasma cell-free DNA isolation and quantitation, and whole-exome sequencing (WES) is provided in the Supplementary Methods.
Custom assay design
Patient-specific somatic variants were identified by comparison of paired primary tumor and matched white blood cell DNA WES profiles for all 49 patients. Clonality of variants was inferred based on the estimated proportion of cancer cells harboring the variant as described in McGranahan and colleagues (23) . Note that clonality inference from samples with low tumor cell fraction was limited due to a fairly flat distribution of variant allele frequency (VAF). The observed VAF in tumor DNA and sequence context of variants were used to prioritize somatic SNVs (single nucleotide variants) and short INDELs identified for each tumor. The bespoke amplicon design pipeline was used to generate PCR primer pairs for the given set of variants. For each patient, 16 highly ranked compatible amplicons were selected for the custom patient-specific panel. The PCR primers were ordered from Integrated DNA Technologies. Details on steps of the workflow are provided in the Supplementary Methods.
Statistical analyses
This study was designed to measure the average time between detection of ctDNA and overt metastases. The target sample size for the EBLIS prospective cohort study was 194, using a 20% patient dropout rate and assuming that 20% of patients will relapse within 2 years. With such a sample size, the mean lead time interval was measured with a precision that extends to AE3 months, with a 95% probability.
All data are presented descriptively as means, medians, or proportions. Relapse-free survival from the day of surgery was determined using the Kaplan-Meier method. Cox proportional hazard regression was used to model the time to disease relapse. Sensitivity is defined as number of patients with preclinical metastasis detected by ctDNA over the total number of patients with clinical relapse. Specificity is defined as the number of patients that were ctDNA negative during the clinical follow-up period over the total number of patients who did not relapse. All statistical analyses were performed using Stata, release 12.0 (Stata Corp.), and survival plots were generated using R version 3.5.1 ("survminer" package version 0.4.2.99; refs. 24, 25) .
Results
Here, we report the analysis of the first 49 patients that entered into the EBLIS study ( Fig. 1 ). The cohort comprised three main subtypes: 34 patients with estrogen receptor-positive, termed herein hormone receptor-positive (HR þ ) and human epidermal growth factor receptor 2-negative (HER2 À ) tumors, eight patients
Translational Relevance
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with HR þ and HER2 þ tumors, and seven patients with triplenegative breast cancer (TNBC ; Table 1 ; Supplementary Table S1 ). Ten patients received neoadjuvant chemotherapy (NACT) prior to breast cancer resection, whereas 39 received no systemic therapy prior to surgery. All except seven patients received adjuvant or NACT with an anthracycline/taxane regimen (Table 1; Supplementary Table S2 ). Thirty-eight patients were receiving adjuvant endocrine therapy throughout the time of blood sampling (Supplementary Table S2 ). Although repeat scans were not required prior to study entry, all except three patients had radiologic imaging performed at diagnosis or at the time of entry into the study, and all were within normal limits ( Supplementary Table  S2 ). At the reporting census date (June 30, 2018), 18 of the 49 patients had relapsed and 31 remained disease-free ( Fig. 2A ).
Clinical validity of ctDNA detection and lead interval
To assess the presence of ctDNA for each patient, assays specific to tumor signatures were designed targeting 16 SNVs and indels identified from the somatic mutation profile of the primary tumor (Supplementary Fig. S2 ; Supplementary Table S3A and S3B). For each patient, we then tested their personalized 16-plex assays across each of their respective plasma samples (range, 1-8 serial samples per patient). Plasma ctDNA was detected in 89% (16 of 18) of the patients who relapsed (Fig. 2 ). By subtype, the sensitivity of the assay was 82%, 100%, and 100% in HR þ /HER2 À , HR þ /HER2 þ , and TNBC, respectively (Fig. 2B ). Two relapsed patients were not detected by ctDNA analysis. The first patient (E009) had three separate foci of primary breast cancer. Exome analysis confirmed a clonal origin with 69 overlapping SNVs between the three tumors. The patient was also recruited at an earlier time point than other patients, with the baseline blood sample drawn just 13 days after the completion of chemotherapy. The 16 SNVs selected from clonal tumor SNVs were undetected in this plasma sample despite sequencing 64 ng total cfDNA at >80,000X. Just 4 months after the patient was recruited, a bone scan showed bony metastases in the sternum, pelvis, and vertebrae. The other patient (E010) had a small resectable local recurrence in the sternum ( Supplementary Table S1 ). The assay achieved 100% specificity, as ctDNA was not detected in any of the 156 plasma samples collected from the 31 patients who did not relapse (Fig. 2) .
All ctDNA-positive patients relapsed within 50 months after surgery, and molecular relapse through ctDNA analysis was detected up to 2 years prior to clinical relapse with a median of 266 days (range, 14-721 days) or 8.9 months (Fig. 2B) . When stratified by subtype, the median lead times for HR þ /HER2 À , HR þ /HER2 þ , and TNBC were 301, 164, and 258 days, respectively 
Detection of driver mutations
Because our method relies upon evolutionary early clonal mutations, we wanted to compare these results with canonical driver genes. Of the 49 patients, 33 (67%) harbored one or more driver genes in the tumor WES, as defined by the genome interpreter (variants identified by WES of tumor DNA were submitted to the cancer genome interpreter; https://www.cancergenomein terpreter.org/home). For the 33 patients, a second assay pool was designed to track as many driver variants as possible. Although results showed concordance between the observed VAF in plasma for patient-specific assays and the driver mutations (Supplemen-tary Fig. S3 ; Supplementary Table S3c ), 17% (4/23) ctDNApositive plasma samples were negative for driver mutations present in the respective tumor exomes. As an example, mutations in CDH1 and ERBB3 genes were undetected in a ctDNA-positive sample E026 time-point 2. The average ctDNA level for this sample was measured at 0.093% VAF by our personalized assay.
ctDNA and other monitoring tests
Concurrent with the plasma ctDNA analyses, additional monitoring tests were also performed, including CT imaging, liver function tests (LFT), and CA 15-3. All CT imaging that was performed prior to clinical relapse was negative ( Supplementary  Table S2 ). Interestingly, for seven patients who had scans within 4 months of their first ctDNA-positive time point, all scans were negative at this point. Similarly, other tests, such as LFTs, were also negative until clinical relapse.
CA 15-3 levels were monitored in 43 of the 49 patients. Of the 18 patients who relapsed, 13 had CA 15-3 measurements; seven had normal CA 15-3 levels, six (30%) had positive CA 15-3 values, but only two patients had progressively rising CA 15-3 levels. Six patients (three relapsed and three nonrelapsed) had an occasional blood sample with slightly elevated CA 15-3, but the levels fluctuated and did not reflect disease progression, whereas all 31 patients who did not relapse were ctDNA negative in 100% of 156 plasma samples. Interestingly, even for the patients that were positive for CA 15-3, ctDNA was detected on average over 200 days ahead of significant CA 15-3 levels ( Supplementary Table  S2 ; Fig. 4A; and Supplementary Fig. S4C ).
In addition to the presence or absence of ctDNA, the levels of ctDNA can also be used to approximate and track disease burden over time as demonstrated by the ctDNA plots for each patient ( Fig. 4; Supplementary Fig. S4 ). In Fig. 4 , we illustrate five patients, representing three cancer subtypes: HR þ /HER2 À (E017 and E026), HER2 þ (E040), and TNBC (E029 and E033). Three patients were initially ctDNA-negative and became positive over time and subsequently had a rise in the ctDNA ahead of clinical relapse (Fig. 4A-C) . The other two patients were ctDNA positive at the earliest monitored time point, and levels increased corresponding to an expected increased tumor burden ( Fig. 4D and E) . In all cases, ctDNA was detected ahead of clinical relapse ( Fig. 4 ; Supplementary Fig. S4 ).
Overall, disease progression can be monitored by both the VAF and the number of detected variants (Fig. 4F ). The median VAF increased from 0.09% in the first positive time point (range, 0.01%-9.22%) to 3.88% (range, 0.05%-64.44%) at the last time point, and the median number of variants detected at the first time point was 5 (range, 2-12) compared with 12 variants (range, 5-15) at the last time point. The low number of variants detected at early time points, each present at very low copy numbers (Supplementary Table S3A ), points to the importance of testing multiple mutations present in a patient's tumor to maximize the probability of early detection.
The individual patient graphs also show the low limit of detection of the assay. For example, patients E017, E029, E033, and E040 had VAFs detected in the range of 0.01% to 0.02% ( Fig. 4B-E; Supplementary Fig. S4 ). The lowest VAF of 0.01% corresponds to the detection of a single mutant molecule in the plasma sample ( Supplementary Figs. S5 and S6) . The average number of mutant molecules per mL of plasma was measured to be less than two in 13 ctDNA-positive samples ( Supplementary  Table S3A ). A low limit of detection with high specificity was achieved by requiring two or more of the 16 variants to be measured above the selected confidence threshold (Supplementary Methods), underscored by the fact that all 156 plasma samples from the 31 nonrecurring patients were negative.
Discussion
Here, we show noninvasive detection of preclinical metastases and earlier identification of breast cancer recurrence across breast cancer subtypes through personalized ctDNA analysis. The approach uses tumor exome data to design patient-specific 16plex assays and ultradeep sequencing of plasma cfDNA at extremely high depth (average of >100,000 reads per target) to achieve a detection sensitivity down to a single mutant molecule.
In this study, we detected ctDNA in 16 of 17 patients with a lead time of up to 2 years (range, 0.5-24 months) prior to distant metastatic relapse, demonstrating the ability of the assay to predict breast cancer recurrence earlier than imaging, CA 15-3, clinical examination, and liver function tests. Previously, Olsson and colleagues profiled patient-specific chromosomal rearrangement breakpoint junctions in 20 patients and demonstrated accurate discrimination between patients with and without clinical detection of recurrence (17) . In 12 of 14 patients, molecular relapse through ctDNA preceded clinical detection of occult metastasis with an average lead time of 11 months (range, 0-37 months). Similarly, Garcia-Murillas and colleagues followed patient-specific point mutations using digital droplet PCR, and in 12 of 15 patients, ctDNA was detected ahead of metastatic relapse with a median lead time of 7.9 months (range, 0.03-13.6 months; ref. 16 ). Our data therefore provide further demonstration that ctDNA can be detected in most patients with breast cancer several months before clinical relapse and with excellent specificity. This presents a window of opportunity for the introduction of non-cross-resistant therapies to prevent overt metastatic relapse. Importantly, once detected, ctDNA remained positive throughout all subsequent monitoring timepoints. In addition to ctDNA detection, circulating tumor cells (CTC) have also shown prognostic significance for detection of preclinical metastases in patients with breast cancer (26) (27) (28) (29) . Both ctDNA and CTCs could therefore complement conventional recurrence monitoring tests that have limited specificity and frequently result in considerable anxiety and expensive follow-up testing.
Using an upfront exome profiling of tumor tissue followed by a personalized targeted multiplex plasma sequencing has distinct advantages. First, this strategy enables detection of ctDNA in all patients regardless of molecular subtype, irrespective of known molecular driver genes. In our study, 100% of all eligible patients were monitored. Previous studies have profiled a small number of genes (i.e., [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] to determine the personalized variants for tracking; however, only 57% to 78% of women have any trackable mutations using such an approach (16, 19, 20) . In our cohort, only 33 of 49 (67%) patients had one or more driver mutations identified in their exome profile, indicating that 16 of 49 patients in this study would not have been able to be monitored using a predetermined gene panel approach based on driver genes.
Second, the outlined approach enables simultaneous interrogation of 16 somatic variants, whereas technologies such as droplet digital PCR or BEAMing are usually designed to monitor either one target or a handful of targets (30) (31) (32) (33) . Increasing evidence suggests that the evolution of cancer is complex and often results in high levels of inter-and intratumor heterogene-ity (34) . Therefore, measuring 16 tumor-specific variants provides a more robust representation of the tumor, enabling more accurate tracking of disease burden.
Third, sequencing a highly targeted panel at a high depth of read (>100,000X) allows for a very low limit of detection at <0.01%. Larger gene panels used for this purpose rarely reach this depth or limit of detection due to the high cost. However, this low level of detection is critical for assessing preclinical metastases as we have shown that variants can be within the range of 0.01% to 0.02% VAF. By using a large volume of plasma (up to 5 mL), we were able to achieve a high assay sensitivity and detect down to 1 ctDNA molecule in 5-mL plasma with a lead time of up to 2 years prior to distant metastatic relapse.
As with all technologies, there are limitations to the outlined approach. The test is not suitable for detecting a second primary breast cancer unless it recurred from the original tumor; this is exemplified by patient E022, where a second contralateral primary cancer was detected ( Supplementary Table S1 ). Second, relying on ctDNA requires that sufficient molecules are present in the plasma at the time of collection, which may not be the case in patients with smaller and less aggressive breast cancers. This is exemplified by patient E010 who relapsed with local resectable disease but was ctDNA negative.
There are some important implications for the future of breast cancer treatment and drug evaluation from our study. In the past, systemic treatment with targeted or cytotoxic therapies has been shown to be curative only when administered in the adjuvant setting; treatment of overt metastatic disease is rarely, if ever, curative (35) . The approach described here offers an alternativethat of attempting to salvage patients who are ctDNA-positive with second-line therapies. In conclusion, we present a sensitive and specific clinical test that can be used to identify preclinical metastases and follow all patients with breast cancer after therapy irrespective of molecular subtype. It out-performs conventional means of monitoring and shows promise as a tool for guiding future precision medicine. Future studies will address the issue of the effects of therapy on ctDNA levels in patients with breast cancer. ) in Natera, Inc. and Gilead. P. Billings holds ownership interest (including patents) in Natera, Inc. and is a consultant/advisory board member for Biological Dynamics, OmniSeq, and Fabric Genomics. M.C. Louie holds ownership interest (including patents) in Natera, Inc. and is a consultant/ advisory board member for Clear Gene. No potential conflicts of interest were disclosed by the other authors.
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